Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).
Dr. Reddy’s Laboratories has disclosed its upcoming schedule of analyst and institutional investor meetings under Indian listing regulations, signaling continued engagement with global capital markets. The disclosure was filed on May 16, 2026, via a Form 6-K with the U.S. Securities and Exchange Commission, underscoring the company’s compliance obligations as a foreign private issuer.
The management plans a series of in-person group meetings from May 20 to June 3, 2026, across Hong Kong, Singapore, Toronto, Boston, New York and Princeton with conferences organized by Elara Capital, Bank of America, Nomura and Investec. The roadshow-style schedule highlights Dr. Reddy’s intent to maintain active dialogue with institutional investors worldwide, although the company notes that timings and meetings may change depending on exigencies for either investors or the company.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on developing, manufacturing and marketing generic medicines, branded formulations and active pharmaceutical ingredients. The company is listed in India and on the New York Stock Exchange, giving it broad access to international capital and a diverse institutional investor base.
Average Trading Volume: 2,563,890
Technical Sentiment Signal: Hold
Current Market Cap: $11.62B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.